Amyloid PET image analyses of PARIS Discovery and MissionAD have been described elsewhere.
6 (link) Briefly, in the PARIS Discovery cohort, three amyloid PET tracers were used: [18F]florbetapir (Amyvid; Lilly Diagnostics), [18F]florbetaben (Neuraceq; Life Molecular Imaging), or [18F]flutemetamol (Vizamyl; GE Healthcare). In the IDEAS study, amyloid PET scans were interpreted visually by local radiologists and nuclear medicine physicians. However, for the PARIS study, these amyloid PET images were obtained and processed centrally by the American College of Radiology by two board‐certified radiologists with amyloid PET tracer‐specific training. Images were quantitatively assessed by standardized uptake value ratio (SUVR) and Centiloid (CL). In the MissionAD data set analyzed for this study, two amyloid PET tracers were used, [18F]florbetapir and [18F]florbetaben, and amyloid PET images were processed centrally by Bioclinica. Image analyses, including SUVR to CL conversion, are described in Hu et al.
6 (link) For the purposes of determining eligibility for MissionAD, PET visual read was used. Based on published evidence, we defined a priori amyloid positivity for our analyses as a CL value greater than 25, which is a more sensitive threshold for brain amyloid plaques than visual read.
15 (link),
16 (link)
6 (link) Briefly, in the PARIS Discovery cohort, three amyloid PET tracers were used: [18F]florbetapir (Amyvid; Lilly Diagnostics), [18F]florbetaben (Neuraceq; Life Molecular Imaging), or [18F]flutemetamol (Vizamyl; GE Healthcare). In the IDEAS study, amyloid PET scans were interpreted visually by local radiologists and nuclear medicine physicians. However, for the PARIS study, these amyloid PET images were obtained and processed centrally by the American College of Radiology by two board‐certified radiologists with amyloid PET tracer‐specific training. Images were quantitatively assessed by standardized uptake value ratio (SUVR) and Centiloid (CL). In the MissionAD data set analyzed for this study, two amyloid PET tracers were used, [18F]florbetapir and [18F]florbetaben, and amyloid PET images were processed centrally by Bioclinica. Image analyses, including SUVR to CL conversion, are described in Hu et al.
6 (link) For the purposes of determining eligibility for MissionAD, PET visual read was used. Based on published evidence, we defined a priori amyloid positivity for our analyses as a CL value greater than 25, which is a more sensitive threshold for brain amyloid plaques than visual read.
15 (link),
16 (link)
